Figure 1. Combined BRAF, MAP2K/MEK and autophagy inhibition in BRAF mutant melanoma. (A) Schematic of concurrent targeting of the MAPK pathway and autophagy. Mu: Mutant. (B) Chest CT images of a stage IV BRAF mutant melanoma patient treated on the BAMM trial with dabrafenib, trametinib and hydroxychloroquine (HCQ). Mo.: Months. Arrow: melanoma metastases to the lung.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
